These innovative agents represent a significant leap in the treatment of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://lilywteu447695.digiblogbox.com/63482840/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide